Navigation Links
Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
Date:9/27/2007

NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb (NYSE: BMY) announced today that Dr. Jeremy Levin has joined the company's Research and Development organization as senior vice president, External Science, Technology and Licensing. He will report to Dr. Elliott Sigal, chief scientific officer and president, Research and Development.

"I am delighted Jeremy has joined our R&D organization at this critical juncture for Bristol-Myers Squibb, as we look to further build our robust pipeline in areas of significant unmet medical need and to transform our pharmaceutical business for the future," said Dr. Sigal. "Jeremy's extensive global network in the pharmaceutical, biotechnology and venture industries will help ensure that we remain a leader in forging creative partnerships to advance the development of novel medicines."

Prior to joining Bristol-Myers Squibb, Dr. Levin served as Global Head of Business Development and Strategic Alliances at the Novartis Institutes of Biomedical Research. In that capacity, he and his team secured hundreds of collaborations in more than 20 countries since 2003. Prior to his tenure at Novartis, Dr. Levin held leadership positions in several biotechnology companies, including Physiome Sciences, Inc. and Cadus Pharmaceutical Corporation. He also was managing director of Perseus Capital LLC, a life sciences venture fund. He has served on the executive committees and boards of several public biosciences companies, as well as the Executive Committee of BIO and the boards of the Biotechnology Institute and the New York Biotechnology Association.

"I am excited about the tremendous opportunity at Bristol-Myers Squibb," said Dr. Levin. "I am especially looking forward
'/>"/>

SOURCE Bristol-Myers Squibb
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Rat joins list of cloned animals
3. Richard Gere Joins Indian Stars For Fight Against AIDS
4. Enbrel Joins with Methotrexate to Cure Rheumatoid Arthritis
5. Anoushka Joins Hands With WFP to Feed the Poor
6. India Joins Hands With Global Body for Vaccine Research
7. Another Statewide Organization Joins the Fight Against Assisted Suicide
8. Two-year-old Joins Mensa, Becomes Its Youngest Ever Genius
9. Senior drug card saves little
10. Reducing Depression In Seniors
11. A sharp increased in senior citizens: set to outpace children.
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18Vivakor Announces New Acquisition Strategy 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 3New drug may reduce heart attack damage 9342 1New drug may reduce heart attack damage 9342 2Change to Win Statement on Minimum Wage Increase 52654 1Neusoft Medicals Latest Innovation NeuViz 16 CT Scanner Approved by FDA for the U S Market 52652 1Neusoft Medicals Latest Innovation NeuViz 16 CT Scanner Approved by FDA for the U S Market 52652 2Neusoft Medicals Latest Innovation NeuViz 16 CT Scanner Approved by FDA for the U S Market 52652 3